메뉴 건너뛰기




Volumn 109, Issue 5, 2013, Pages 834-845

High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials

Author keywords

Clopidogrel; P2Y12 antagonists; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; COLLAGEN; CYCLOOXYGENASE 1; DICLOFENAC; DIPYRONE; FLUFENAMIC ACID; GALLIC ACID; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MEFENAMIC ACID; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; PARACETAMOL; PHENAZONE; PIROXICAM; PROPYPHENAZONE; PROSTAGLANDIN ENDOPEROXIDE; PROSTAGLANDIN H2; SULINDAC; THROMBOXANE A2; THROMBOXANE SYNTHASE; TIAPROFENIC ACID;

EID: 84877065458     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-08-0588     Document Type: Article
Times cited : (32)

References (96)
  • 1
    • 0346688615 scopus 로고    scopus 로고
    • Antiplatelet therapy for ischaemic heart disease
    • Lange RA, Hillis LD. Antiplatelet therapy for ischaemic heart disease. N Engl J Med 2004; 350: 277-280.
    • (2004) N Engl J Med , vol.350 , pp. 277-280
    • Lange, R.A.1    Hillis, L.D.2
  • 2
    • 0020528647 scopus 로고
    • Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a veterans administration cooperative study
    • Lewis HD, Jr., Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a veterans administration cooperative study. N Engl J Med 1983; 309: 396-403.
    • (1983) N Engl J Med , vol.309 , pp. 396-403
    • Lewis Jr., H.D.1    Davis, J.W.2    Archibald, D.G.3
  • 3
    • 0022375287 scopus 로고
    • Aspirin, sulfinpyrazone, or both in unstable angina. Results of a canadian multicenter trial
    • Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a canadian multicenter trial. N Engl J Med 1985; 313: 1369-1375.
    • (1985) N Engl J Med , vol.313 , pp. 1369-1375
    • Cairns, J.A.1    Gent, M.2    Singer, J.3
  • 4
    • 0023754429 scopus 로고
    • Aspirin, heparin, or both to treat acute unstable angina
    • Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
    • (1988) N Engl J Med , vol.319 , pp. 1105-1111
    • Theroux, P.1    Ouimet, H.2    McCans, J.3
  • 5
    • 0030053912 scopus 로고    scopus 로고
    • Platelet function in acute myocardial infarction treated with direct angioplasty
    • Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
    • (1996) Circulation , vol.93 , pp. 229-237
    • Gawaz, M.1    Neumann, F.J.2    Ott, I.3
  • 6
    • 0030033339 scopus 로고    scopus 로고
    • Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stenting
    • Neumann FJ, Gawaz M, Ott I, et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stenting. J Am Coll Cardiol 1996; 27: 15-21.
    • (1996) J Am Coll Cardiol , vol.27 , pp. 15-21
    • Neumann, F.J.1    Gawaz, M.2    Ott, I.3
  • 7
    • 9244251971 scopus 로고    scopus 로고
    • A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
    • Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
    • (1996) N Engl J Med , vol.334 , pp. 1084-1089
    • Schömig, A.1    Neumann, F.J.2    Kastrati, A.3
  • 8
    • 0034622539 scopus 로고    scopus 로고
    • Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
    • Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
    • (2000) Circulation , vol.102 , pp. 624-629
    • Bertrand, M.E.1    Rupprecht, H.J.2    Urban, P.3
  • 9
    • 0034762075 scopus 로고    scopus 로고
    • Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
    • Müller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
    • (2001) Heart , vol.85 , pp. 92-93
    • Müller, I.1    Seyfarth, M.2    Rudiger, S.3
  • 10
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • The Clopidogrel in Unstable Angina to Prevent Recurrent Ischaemic Events Trial Investigators
    • The Clopidogrel in Unstable Angina to Prevent Recurrent Ischaemic Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
    • (2001) N Engl J Med , vol.345 , pp. 494-502
  • 11
    • 20144373281 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    • Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
    • (2005) N Engl J Med , vol.352 , pp. 1179-1189
    • Sabatine, M.S.1    Cannon, C.P.2    Gibson, C.M.3
  • 12
    • 37549006004 scopus 로고    scopus 로고
    • The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score
    • Geisler T, Grass D, Bigalke B, et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
    • (2008) J Thromb Haemost , vol.6 , pp. 54-61
    • Geisler, T.1    Grass, D.2    Bigalke, B.3
  • 13
    • 27744516843 scopus 로고    scopus 로고
    • Absorption, metabolisation, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral doses for Immediate Clopidogrel Effect) trial
    • von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolisation, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral doses for Immediate Clopidogrel Effect) trial. Circulation 2005; 112: 2946-2950.
    • (2005) Circulation , vol.112 , pp. 2946-2950
    • von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3
  • 14
    • 33845451677 scopus 로고    scopus 로고
    • A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation
    • Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66 e9-16.
    • (2007) Am Heart J , vol.153 , Issue.66
    • Brandt, J.T.1    Payne, C.D.2    Wiviott, S.D.3
  • 15
    • 81255136664 scopus 로고    scopus 로고
    • Thienopyridine-associated drug-drug interactions: Pharmacologic mechanisms and clinical relevance
    • Hulot JS, Collet JP, Montalescot G. Thienopyridine-associated drug-drug interactions: Pharmacologic mechanisms and clinical relevance. Curr Cardiol Rep 2011; 13: 451-458.
    • (2011) Curr Cardiol Rep , vol.13 , pp. 451-458
    • Hulot, J.S.1    Collet, J.P.2    Montalescot, G.3
  • 16
    • 55449137355 scopus 로고    scopus 로고
    • CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
    • Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9: 1251-1259.
    • (2008) Pharmacogenomics , vol.9 , pp. 1251-1259
    • Geisler, T.1    Schaeffeler, E.2    Dippon, J.3
  • 17
    • 43049179414 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    • Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1925-1934
    • Trenk, D.1    Hochholzer, W.2    Fromm, M.F.3
  • 18
    • 77952591958 scopus 로고    scopus 로고
    • Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
    • Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2427-2434
    • Hochholzer, W.1    Trenk, D.2    Fromm, M.F.3
  • 19
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome P-450 polymorphisms and response to clopidogrel
    • Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    • (2009) N Engl J Med , vol.360 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 20
    • 0033678468 scopus 로고    scopus 로고
    • Identification and biological activity of the active metabolite of clopidogrel
    • Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
    • (2000) Thromb Haemost , vol.84 , pp. 891-896
    • Savi, P.1    Pereillo, J.M.2    Uzabiaga, M.F.3
  • 21
    • 0038508970 scopus 로고    scopus 로고
    • The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
    • Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-59.
    • (2003) Drug Metab Dispos , vol.31 , pp. 53-59
    • Clarke, T.A.1    Waskell, L.A.2
  • 22
    • 73149119363 scopus 로고    scopus 로고
    • Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    • Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
    • (2010) Drug Metab Dispos , vol.38 , pp. 92-99
    • Kazui, M.1    Nishiya, Y.2    Ishizuka, T.3
  • 24
    • 0037422534 scopus 로고    scopus 로고
    • Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction
    • Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003; 107: 32-37.
    • (2003) Circulation , vol.107 , pp. 32-37
    • Lau, W.C.1    Waskell, L.A.2    Watkins, P.B.3
  • 25
    • 38349168982 scopus 로고    scopus 로고
    • Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement
    • Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99: 174-181.
    • (2008) Thromb Haemost , vol.99 , pp. 174-181
    • Trenk, D.1    Hochholzer, W.2    Frundi, D.3
  • 26
    • 78650517232 scopus 로고    scopus 로고
    • Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies
    • Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 65-74.
    • (2011) Clin Pharmacol Ther , vol.89 , pp. 65-74
    • Angiolillo, D.J.1    Gibson, C.M.2    Cheng, S.3
  • 27
    • 78149487926 scopus 로고    scopus 로고
    • Clopidogrel with or without omeprazole in coronary artery disease
    • Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.
    • (2010) N Engl J Med , vol.363 , pp. 1909-1917
    • Bhatt, D.L.1    Cryer, B.L.2    Contant, C.F.3
  • 28
    • 77953896604 scopus 로고    scopus 로고
    • Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis
    • Hulot J-S, Collet J-P, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-143.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 134-143
    • Hulot, J.-S.1    Collet, J.-P.2    Silvain, J.3
  • 29
    • 54349121974 scopus 로고    scopus 로고
    • Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
    • Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 1557-1563
    • Siller-Matula, J.M.1    Lang, I.2    Christ, G.3
  • 30
    • 77952048536 scopus 로고    scopus 로고
    • The use of amlodipine, but not of p-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
    • Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of p-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
    • (2010) Thromb Haemost , vol.103 , pp. 920-925
    • Harmsze, A.M.1    Robijns, K.2    van Werkum, J.W.3
  • 31
    • 34247181997 scopus 로고    scopus 로고
    • In vitro metabolism of antiplatelet agent clopidogrel: Cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation
    • Kurihara A, Hagihara K, Kazui M, et al. In vitro metabolism of antiplatelet agent clopidogrel: Cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev 2005; 37: 99.
    • (2005) Drug Metab Rev , vol.37 , pp. 99
    • Kurihara, A.1    Hagihara, K.2    Kazui, M.3
  • 32
    • 33749339075 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    • Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
    • (2006) Blood , vol.108 , pp. 2244-2247
    • Hulot, J.S.1    Bura, A.2    Villard, E.3
  • 33
    • 0033828454 scopus 로고    scopus 로고
    • The CYP219 enzyme polymorphism
    • Wedlund PJ. The CYP219 enzyme polymorphism. Pharmacology 2000; 61: 174-183.
    • (2000) Pharmacology , vol.61 , pp. 174-183
    • Wedlund, P.J.1
  • 34
    • 0036394942 scopus 로고    scopus 로고
    • Clinical significance of the cytochrome P450 2C19 genetic polymorphism
    • Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958.
    • (2002) Clin Pharmacokinet , vol.41 , pp. 913-958
    • Desta, Z.1    Zhao, X.2    Shin, J.G.3
  • 35
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
    • Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373: 309-317.
    • (2009) Lancet , vol.373 , pp. 309-317
    • Collet, J.P.1    Hulot, J.S.2    Pena, A.3
  • 36
    • 65249145201 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
    • Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
    • (2009) Eur Heart J , vol.30 , pp. 916-922
    • Sibbing, D.1    Stegherr, J.2    Latz, W.3
  • 37
    • 58749090547 scopus 로고    scopus 로고
    • Genetic determinants of response to clopidogrel and cardiovascular events
    • Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
    • (2009) N Engl J Med , vol.360 , pp. 363-375
    • Simon, T.1    Verstuyft, C.2    Mary-Krause, M.3
  • 38
    • 78049326068 scopus 로고    scopus 로고
    • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis
    • Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. J Am Med Assoc 2010; 304: 1821-1830.
    • (2010) J Am Med Assoc , vol.304 , pp. 1821-1830
    • Mega, J.L.1    Simon, T.2    Collet, J.P.3
  • 39
    • 30344457586 scopus 로고    scopus 로고
    • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    • Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 103-113
    • Sim, S.C.1    Risinger, C.2    Dahl, M.L.3
  • 40
    • 67949120411 scopus 로고    scopus 로고
    • The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
    • Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009; 7: 1409-1411.
    • (2009) J Thromb Haemost , vol.7 , pp. 1409-1411
    • Frere, C.1    Cuisset, T.2    Gaborit, B.3
  • 41
    • 77955416969 scopus 로고    scopus 로고
    • Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
    • Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8: 1685-1693.
    • (2010) J Thromb Haemost , vol.8 , pp. 1685-1693
    • Sibbing, D.1    Gebhard, D.2    Koch, W.3
  • 42
    • 85027923345 scopus 로고    scopus 로고
    • The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
    • Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175.
    • (2012) Pharmacogenet Genomics , vol.22 , pp. 169-175
    • Harmsze, A.M.1    van Werkum, J.W.2    Hackeng, C.M.3
  • 43
    • 84863082704 scopus 로고    scopus 로고
    • The gain-of-function variant allele CYP2C19*17: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients
    • Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. Journal of Thrombosis and Haemostasis 2012; 10: 199-206.
    • (2012) Journal of Thrombosis and Haemostasis , vol.10 , pp. 199-206
    • Li, Y.1    Tang, H.L.2    Hu, Y.F.3
  • 44
    • 84155167902 scopus 로고    scopus 로고
    • Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
    • Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-108.
    • (2012) Heart , vol.98 , pp. 100-108
    • Zabalza, M.1    Subirana, I.2    Sala, J.3
  • 45
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    • Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
    • (2009) J Am Med Assoc , vol.302 , pp. 849-857
    • Shuldiner, A.R.1    O'Connell, J.R.2    Bliden, K.P.3
  • 47
    • 77958100874 scopus 로고    scopus 로고
    • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the plato trial
    • Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the plato trial. The Lancet 2010; 376: 1320-1328.
    • (2010) The Lancet , vol.376 , pp. 1320-1328
    • Wallentin, L.1    James, S.2    Storey, R.F.3
  • 48
    • 84861329078 scopus 로고    scopus 로고
    • ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis
    • Luo M, Li J, Xu X, et al. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis. Thromb Res 2012; 129: 754-759.
    • (2012) Thromb Res , vol.129 , pp. 754-759
    • Luo, M.1    Li, J.2    Xu, X.3
  • 49
    • 78651239845 scopus 로고    scopus 로고
    • Paraoxonase-1 is a major determinant of clopidogrel efficacy
    • Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
    • (2011) Nat Med , vol.17 , pp. 110-116
    • Bouman, H.J.1    Schömig, E.2    van Werkum, J.W.3
  • 50
    • 79960012663 scopus 로고    scopus 로고
    • No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
    • Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32: 1605-1613.
    • (2011) Eur Heart J , vol.32 , pp. 1605-1613
    • Sibbing, D.1    Koch, W.2    Massberg, S.3
  • 51
    • 80052790906 scopus 로고    scopus 로고
    • Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
    • Trenk D, Hochholzer W, Fromm MF, et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4: 429-436.
    • (2011) Circ Cardiovasc Genet , vol.4 , pp. 429-436
    • Trenk, D.1    Hochholzer, W.2    Fromm, M.F.3
  • 52
    • 84863500468 scopus 로고    scopus 로고
    • Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis
    • Reny JL, Combescure C, Daali Y, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis. J Thrombos Haemostas 2012; 10: 1242-1251.
    • (2012) J Thrombos Haemostas , vol.10 , pp. 1242-1251
    • Reny, J.L.1    Combescure, C.2    Daali, Y.3
  • 53
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    • (2007) N Engl J Med , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1    Braunwald, E.2    McCabe, C.H.3
  • 54
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 55
    • 33645105318 scopus 로고    scopus 로고
    • Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
    • Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-607.
    • (2006) Drug Metab Dispos , vol.34 , pp. 600-607
    • Rehmel, J.L.1    Eckstein, J.A.2    Farid, N.A.3
  • 56
    • 36348943475 scopus 로고    scopus 로고
    • Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    • Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-2436.
    • (2007) J Thromb Haemost , vol.5 , pp. 2429-2436
    • Brandt, J.T.1    Close, S.L.2    Iturria, S.J.3
  • 57
    • 66349133650 scopus 로고    scopus 로고
    • Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    • Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
    • (2009) Circulation , vol.119 , pp. 2553-2560
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 58
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
    • Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116: 2923-2932.
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3
  • 59
    • 78650209342 scopus 로고    scopus 로고
    • Ticagrelor: From discovery to phase III clinical trial
    • Siller-Matula JM, Jilma B. Ticagrelor: From discovery to phase III clinical trial. Future Cardiol 2010; 6: 753-764.
    • (2010) Future Cardiol , vol.6 , pp. 753-764
    • Siller-Matula, J.M.1    Jilma, B.2
  • 60
    • 77955992168 scopus 로고    scopus 로고
    • Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects
    • Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010; 38: 1514-1521.
    • (2010) Drug Metab Dispos , vol.38 , pp. 1514-1521
    • Teng, R.1    Oliver, S.2    Hayes, M.A.3
  • 61
    • 73949112820 scopus 로고    scopus 로고
    • Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
    • Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
    • (2009) Circulation , vol.120 , pp. 2577-2585
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3
  • 62
    • 0035967496 scopus 로고    scopus 로고
    • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-assessing ULTEGRA) multicenter study
    • Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-assessing ULTEGRA) multicenter study. Circulation 2001; 103: 2572-2578.
    • (2001) Circulation , vol.103 , pp. 2572-2578
    • Steinhubl, S.R.1    Talley, J.D.2    Braden, G.A.3
  • 63
    • 0038649988 scopus 로고    scopus 로고
    • Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
    • Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
    • (2003) Circulation , vol.107 , pp. 2908-2913
    • Gurbel, P.A.1    Bliden, K.P.2    Hiatt, B.L.3
  • 64
    • 11844256436 scopus 로고    scopus 로고
    • Variability in platelet responsiveness to clopidogrel among 544 individuals
    • Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 246-251
    • Serebruany, V.L.1    Steinhubl, S.R.2    Berger, P.B.3
  • 65
    • 33750479499 scopus 로고    scopus 로고
    • Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
    • Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 1742-1750
    • Hochholzer, W.1    Trenk, D.2    Bestehorn, H.P.3
  • 66
    • 0038354521 scopus 로고    scopus 로고
    • Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilatorstimulated phosphoprotein phosphorylation
    • Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilatorstimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
    • (2003) Catheter Cardiovasc Interv , vol.59 , pp. 295-302
    • Barragan, P.1    Bouvier, J.L.2    Roquebert, P.O.3
  • 67
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
    • Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
    • (2004) Circulation , vol.109 , pp. 3171-3175
    • Matetzky, S.1    Shenkman, B.2    Guetta, V.3
  • 68
    • 77956353401 scopus 로고    scopus 로고
    • Prognostic significance of high onclopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis
    • Aradi D, Komocsi A, Vorobcsuk A, et al. Prognostic significance of high onclopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010; 160: 543-551.
    • (2010) Am Heart J , vol.160 , pp. 543-551
    • Aradi, D.1    Komocsi, A.2    Vorobcsuk, A.3
  • 69
    • 80052167250 scopus 로고    scopus 로고
    • Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: A collaborative meta-analysis of individual participant data
    • Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-1954.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 1945-1954
    • Brar, S.S.1    ten Berg, J.2    Marcucci, R.3
  • 70
    • 77953911457 scopus 로고    scopus 로고
    • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    • Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 919-933
    • Bonello, L.1    Tantry, U.S.2    Marcucci, R.3
  • 72
    • 79952598836 scopus 로고    scopus 로고
    • Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention
    • Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. J Am Med Assoc 2011; 305: 1097-1105.
    • (2011) J Am Med Assoc , vol.305 , pp. 1097-1105
    • Price, M.J.1    Berger, P.B.2    Teirstein, P.S.3
  • 73
    • 0032481092 scopus 로고    scopus 로고
    • A clinical trial comparing three antithrombotic- drug regimens after coronary-artery stenting
    • Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic- drug regimens after coronary-artery stenting. N Engl J Med 1998; 339: 1665-1671.
    • (1998) N Engl J Med , vol.339 , pp. 1665-1671
    • Leon, M.B.1    Baim, D.S.2    Popma, J.J.3
  • 74
    • 34250020766 scopus 로고    scopus 로고
    • Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
    • Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 2312-2317
    • Buonamici, P.1    Marcucci, R.2    Migliorini, A.3
  • 75
    • 44949173754 scopus 로고    scopus 로고
    • Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    • Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
    • (2008) Eur Heart J , vol.29 , pp. 992-1000
    • Price, M.J.1    Endemann, S.2    Gollapudi, R.R.3
  • 76
    • 84861857758 scopus 로고    scopus 로고
    • A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing platelet Reactivity In patients under- Going elective stent placement on clopidogrel to Guide alternative thErapy with pRasugrel) study
    • Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing platelet Reactivity In patients under- Going elective stent placement on clopidogrel to Guide alternative thErapy with pRasugrel) study. J Am Coll Cardiol 2012; 59: 2159-2164.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 2159-2164
    • Trenk, D.1    Stone, G.W.2    Gawaz, M.3
  • 77
    • 84877021553 scopus 로고    scopus 로고
    • A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after DES implantation. Results from the ADAPT-DES study
    • Abstract LBCT
    • Stone GW. A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after DES implantation. Results from the ADAPT-DES study. J Am Coll Cardiol 2011; 58 (Suppl B): xii Abstract LBCT.
    • (2011) J Am Coll Cardiol , vol.58 , Issue.SUPPL. B
    • Stone, G.W.1
  • 78
    • 84883291850 scopus 로고    scopus 로고
    • Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
    • epub ahead of print
    • Aradi D, Komocsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2012; epub ahead of print.
    • (2012) Int J Cardiol
    • Aradi, D.1    Komocsi, A.2    Price, M.J.3
  • 79
    • 77956290748 scopus 로고    scopus 로고
    • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes
    • Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-942.
    • (2010) N Engl J Med , vol.363 , pp. 930-942
    • Mehta, S.R.1    Bassand, J.P.2    Chrolavicius, S.3
  • 80
    • 77958005516 scopus 로고    scopus 로고
    • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT- OASIS 7): A randomised factorial trial
    • Mehta SR, Tanguay J-F, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT- OASIS 7): A randomised factorial trial. Lancet 2010; 376: 1233-1243.
    • (2010) Lancet , vol.376 , pp. 1233-1243
    • Mehta, S.R.1    Tanguay, J.-F.2    Eikelboom, J.W.3
  • 81
    • 79956142994 scopus 로고    scopus 로고
    • Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularisation
    • Raber L, Juni P, Nuesch E, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularisation. J Am Coll Cardiol 2011; 57: 2143-2151.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 2143-2151
    • Raber, L.1    Juni, P.2    Nuesch, E.3
  • 82
    • 79954416871 scopus 로고    scopus 로고
    • A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (A prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial
    • Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (A prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol 2011; 57: 1700-1708.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1700-1708
    • Stone, G.W.1    Teirstein, P.S.2    Meredith, I.T.3
  • 83
    • 79955056445 scopus 로고    scopus 로고
    • Clinical evaluation of the RESOLUTE zotarolimus- eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial
    • Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the RESOLUTE zotarolimus- eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial. J Am Coll Cardiol 2011; 57: 1778-1783.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1778-1783
    • Yeung, A.C.1    Leon, M.B.2    Jain, A.3
  • 84
    • 79960603731 scopus 로고    scopus 로고
    • High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes
    • Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467-473.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 467-473
    • Bonello, L.1    Pansieri, M.2    Mancini, J.3
  • 85
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
    • (2010) Circulation , vol.121 , pp. 512-518
    • Sibbing, D.1    Koch, W.2    Gebhard, D.3
  • 86
    • 84866861394 scopus 로고    scopus 로고
    • Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at one year follow-up in patients receiving prasugrel
    • Bonello L, Mancini J, Pansieri M, et al. Relationship between post-treatment platelet reactivity and ischaemic and bleeding events at one year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
    • (2012) J Thromb Haemost , vol.10 , pp. 1999-2005
    • Bonello, L.1    Mancini, J.2    Pansieri, M.3
  • 87
    • 84866618180 scopus 로고    scopus 로고
    • Personalizing antiplatelet therapy with clopidogrel
    • Trenk D, Zolk O, Fromm MF, et al. Personalizing antiplatelet therapy with clopidogrel. Clin Pharmacol Ther 2012; 92: 476-485.
    • (2012) Clin Pharmacol Ther , vol.92 , pp. 476-485
    • Trenk, D.1    Zolk, O.2    Fromm, M.F.3
  • 88
    • 41249093357 scopus 로고    scopus 로고
    • Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
    • Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1404-1411
    • Bonello, L.1    Camoin-Jau, L.2    Arques, S.3
  • 89
    • 58149476444 scopus 로고    scopus 로고
    • Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
    • Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
    • (2009) Am J Cardiol , vol.103 , pp. 5-10
    • Bonello, L.1    Camoin-Jau, L.2    Armero, S.3
  • 90
    • 48349103357 scopus 로고    scopus 로고
    • Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3t/2r). Rationale for the study and protocol design
    • Valgimigli M, Campo G, de Cesare N, et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3t/2r). Rationale for the study and protocol design. Cardiovasc Drugs Ther 2008; 22: 313-320.
    • (2008) Cardiovasc Drugs Ther , vol.22 , pp. 313-320
    • Valgimigli, M.1    Campo, G.2    de Cesare, N.3
  • 91
    • 57549099501 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study
    • Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study. JACC Cardiovasc Interv 2008; 1: 649-653.
    • (2008) JACC Cardiovasc Interv , vol.1 , pp. 649-653
    • Cuisset, T.1    Frere, C.2    Quilici, J.3
  • 92
    • 84858280313 scopus 로고    scopus 로고
    • Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity
    • Aradi D, Rideg O, Vorobcsuk A, et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest 2012; 42: 384-392.
    • (2012) Eur J Clin Invest , vol.42 , pp. 384-392
    • Aradi, D.1    Rideg, O.2    Vorobcsuk, A.3
  • 93
    • 84861230787 scopus 로고    scopus 로고
    • The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (The EFFICIENT trial)
    • Ari H, Ozkan H, Karacinar A, et al. The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (The EFFICIENT trial). Int J Cardiol 2012; 157: 374-380.
    • (2012) Int J Cardiol , vol.157 , pp. 374-380
    • Ari, H.1    Ozkan, H.2    Karacinar, A.3
  • 94
    • 84862773918 scopus 로고    scopus 로고
    • Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischaemic complications after percutaneous coronary intervention
    • Hazarbasanov D, Velchev V, Finkov B, et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischaemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 2012; 34: 85-90.
    • (2012) J Thromb Thrombolysis , vol.34 , pp. 85-90
    • Hazarbasanov, D.1    Velchev, V.2    Finkov, B.3
  • 95
    • 79955926318 scopus 로고    scopus 로고
    • Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance
    • Wang XD, Zhang DF, Zhuang SW, et al. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 2011; 34: 332-338.
    • (2011) Clin Cardiol , vol.34 , pp. 332-338
    • Wang, X.D.1    Zhang, D.F.2    Zhuang, S.W.3
  • 96
    • 84870032410 scopus 로고    scopus 로고
    • Bedside monitoring to adjust antiplatelet therapy for coronary stenting
    • Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
    • (2012) N Engl J Med , vol.367 , pp. 2100-2109
    • Collet, J.-P.1    Cuisset, T.2    Rangé, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.